Ina Oehme

5.5k total citations · 1 hit paper
65 papers, 3.6k citations indexed

About

Ina Oehme is a scholar working on Molecular Biology, Neurology and Oncology. According to data from OpenAlex, Ina Oehme has authored 65 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Molecular Biology, 20 papers in Neurology and 14 papers in Oncology. Recurrent topics in Ina Oehme's work include Histone Deacetylase Inhibitors Research (43 papers), Protein Degradation and Inhibitors (32 papers) and Neuroblastoma Research and Treatments (20 papers). Ina Oehme is often cited by papers focused on Histone Deacetylase Inhibitors Research (43 papers), Protein Degradation and Inhibitors (32 papers) and Neuroblastoma Research and Treatments (20 papers). Ina Oehme collaborates with scholars based in Germany, United States and France. Ina Oehme's co-authors include Olaf Witt, Hedwig E. Deubzer, Till Milde, Marco Lodrini, Manfred Jung, Wolfgang Sippl, Andreas von Deimling, Annette Kopp‐Schneider, Christophe Romier and E Koeneke and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Nucleic Acids Research.

In The Last Decade

Ina Oehme

60 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

HDAC family: What are the cancer relevant targets?

2008 871 citations Olaf Witt, Hedwig E. Deubzer et al. Cancer Letters profile →

Peers

Countries citing papers authored by Ina Oehme

Since Specialization

Citations

This map shows the geographic impact of Ina Oehme's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ina Oehme with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ina Oehme more than expected).

Fields of papers citing papers by Ina Oehme

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ina Oehme. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ina Oehme. The network helps show where Ina Oehme may publish in the future.

Co-authorship network of co-authors of Ina Oehme

This figure shows the co-authorship network connecting the top 25 collaborators of Ina Oehme. A scholar is included among the top collaborators of Ina Oehme based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ina Oehme. Ina Oehme is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identification of a Proteolysis‐Targeting‐Chimera that Addresses Activated Checkpoint Kinase‐1 Reveals its Non‐Catalytic Functions in Tumor Cells 2025 ·Angewandte Chemie International Edition ·(unknown), Mohamed Abdelsalam, (unknown), (unknown), (unknown), (unknown), Matthias Schmidt, Sara Najafi, Ina Oehme, Matthias Bros, Jia‐Xuan Chen, Mario Dejung, Wolfgang Sippl, Oliver H. Krämer	0
2	Genomic and phenotypic stability of fusion-driven pediatric sarcoma cell lines 2025 ·Nature Communications ·(unknown), (unknown), (unknown), Martin Sill, Rupert Öllinger, (unknown), Enrique de Álava, Didier Surdez, Uta Dirksen, Ina Oehme, Katia Scotlandi, Olivier Delattre, Martina Müller‐Nurasyid, Roland Rad, Konstantin Strauch, T. Grünewald, Florencia Cidre‐Aranaz	2
3	Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins 2024 ·Leukemia ·(unknown), Mohamed Abdelsalam, (unknown), (unknown), Caroline Alvares, Matthias Schmidt, Walburgis Brenner, Sara Najafi, Ina Oehme, (unknown), (unknown), Matthias Bros, Wolfgang Sippl, Oliver H. Krämer	12
4	Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours 2024 ·British Journal of Cancer ·(unknown), (unknown), Duy Nguyen, (unknown), (unknown), Sara Najafi, (unknown), (unknown), Norman Mack, (unknown), Frank Westermann, Matthias Schlesner, Till Milde, Marcel Kool, Tim Holland‐Letz, Meike Vogler, Heike Peterziel, Olaf Witt, Ina Oehme	1
5	Key Pharmacokinetic Parameters of 74 Pediatric Anticancer Drugs Providing Assistance in Preclinical Studies 2023 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), (unknown), (unknown), (unknown), Jonas Ecker, (unknown), Julia Benzel, Heike Peterziel, Kristian W. Pajtler, Cornelis M. van Tilburg, Ina Oehme, Olaf Witt, Till Milde	3
6	Generation of patient-derived pediatric pilocytic astrocytoma in-vitro models using SV40 large T: evaluation of a modeling workflow 2023 ·Journal of Neuro-Oncology ·Florian Selt, Ahmed El Damaty, Martin U. Schuhmann, (unknown), Jonas Ecker, Philipp Sievers, (unknown), Christel Herold‐Mende, Ina Oehme, Andreas von Deimling, Stefan M. Pfister, Felix Sahm, David Jones, Olaf Witt, Till Milde	1
7	Synthesis, Biochemical, and Cellular Evaluation of HDAC6 Targeting Proteolysis Targeting Chimeras 2022 ·Methods in molecular biology ·(unknown), Tino Heimburg, Johannes Ridinger, Daniel Herp, Matthias Schmidt, Christophe Romier, Manfred Jung, Ina Oehme, Wolfgang Sippl	7
8	Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity 2022 ·International Journal of Molecular Sciences ·(unknown), (unknown), Tino Heimburg, Daniel Herp, (unknown), (unknown), Johannes Ridinger, Dina Robaa, (unknown), Frank Erdmann, Matthias Schmidt, Christophe Romier, Manfred Jung, Ina Oehme, Wolfgang Sippl	27
9	Patient-by-Patient Deep Transfer Learning for Drug-Response Profiling Using Confocal Fluorescence Microscopy of Pediatric Patient-Derived Tumor-Cell Spheroids 2022 ·IEEE Transactions on Medical Imaging ·Yannick Berker, (unknown), Heike Peterziel, Petra Fiesel, Olaf Witt, Ina Oehme, Matthias Schlesner, Sina Oppermann	5
10	First Fluorescent Acetylspermidine Deacetylation Assay for HDAC10 Identifies Selective Inhibitors with Cellular Target Engagement** 2022 ·ChemBioChem ·Daniel Herp, Johannes Ridinger, Dina Robaa, Stephen A. Shinsky, (unknown), (unknown), (unknown), Raphael R. Steimbach, Corey J. Herbst‐Gervasoni, (unknown), Christophe Romier, Peter Sehr, Nikolas Gunkel, Aubry K. Miller, David W. Christianson, Ina Oehme, Wolfgang Sippl, Manfred Jung	18
11	Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated 2019 ·Journal of Medicinal Chemistry ·(unknown), Michael Morgen, Peter Sehr, Raphael R. Steimbach, Davide Moi, Johannes Ridinger, Ina Oehme, Olaf Witt, Mona Malz, Mauro S. Nogueira, Oliver Koch, Nikolas Gunkel, Aubry K. Miller	66
12	The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines 2018 ·Archives of Toxicology ·Fiona R. Kolbinger, E Koeneke, Johannes Ridinger, Tino Heimburg, Michael Müller, (unknown), Wolfgang Sippl, Manfred Jung, Nikolas Gunkel, Aubry K. Miller, Frank Westermann, Olaf Witt, Ina Oehme	28
13	The enzyme activity of histone deacetylase 8 is modulated by a redox-switch 2018 ·Redox Biology ·(unknown), Christian Meyners, (unknown), (unknown), Olaf Witt, Ina Oehme, Franz‐Josef Meyer‐Almes	40
14	Inhibition of Histone Deacetylases Permits Lipopolysaccharide-Mediated Secretion of Bioactive IL-1β via a Caspase-1–Independent Mechanism 2015 ·The Journal of Immunology ·(unknown), Tatjana Eigenbrod, (unknown), Julia-Stefanie Frick, Matthew J. Sweet, Melanie R. Shakespear, Jonathan Jantsch, (unknown), (unknown), Julian D. Langer, Ina Oehme, Liliana Schaefer, André Fischer, (unknown), Klaus Heeg, Alexander H. Dalpke, Konrad A. Bode	39
15	Histone deacetylase 10-promoted autophagy as a druggable point of interference to improve the treatment response of advanced neuroblastomas 2013 ·Autophagy ·Ina Oehme, Marco Lodrini, Nathan Brady, Olaf Witt	17
16	Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer 2012 ·BMC Cancer ·(unknown), (unknown), Thilo Hackert, Ina Oehme, Olaf Witt, Klaus Felix, Nathalia A. Giese, Jens Werner	37
17	HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth 2010 ·Clinical Cancer Research ·Till Milde, Ina Oehme, Andrey Korshunov, Annette Kopp‐Schneider, Marc Remke, Paul A. Northcott, Hedwig E. Deubzer, Marco Lodrini, Michael D. Taylor, Andreas von Deimling, Stefan M. Pfister, Olaf Witt	158
18	Targeting Histone Deacetylases in Neuroblastoma 2009 ·Current Pharmaceutical Design ·Olaf Witt, Hedwig E. Deubzer, Marco Lodrini, Till Milde, Ina Oehme	53
19	Histone Deacetylase 8 in Neuroblastoma Tumorigenesis 2008 ·Clinical Cancer Research ·Ina Oehme, Hedwig E. Deubzer, Dennis Wegener, Diana Pickert, (unknown), Barbara Hero, Annette Kopp‐Schneider, Frank Westermann, Scott M. Ulrich, Andreas von Deimling, Matthias Fischer, Olaf Witt	320
20	HDAC family: What are the cancer relevant targets? breakdown → 2008 ·Cancer Letters ·Olaf Witt, Hedwig E. Deubzer, Till Milde, Ina Oehme	871

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact